Citation: Mengmeng Yuan, Xiwen Hu, Na Li, Limin Xu, Mengxi Zhu, Xing Pei, Rui Li, Lu Sun, Yupeng Chen, Fei Yu, Huining He. Kidney targeted delivery of siRNA mediated by peptide-siRNA conjugate for the treatment of acute kidney injury[J]. Chinese Chemical Letters, ;2025, 36(6): 110251. doi: 10.1016/j.cclet.2024.110251 shu

Kidney targeted delivery of siRNA mediated by peptide-siRNA conjugate for the treatment of acute kidney injury

Mengmeng Yuan ^{b, d, 1} ,
Xiwen Hu ^{a, b, 1} ,
Na Li ^{c, 1} ,
Limin Xu ^b ,
Mengxi Zhu ^b ,
Xing Pei ^e ,
Rui Li ^b ,
Lu Sun ^b ,
Yupeng Chen ^c ,
Fei Yu ^b ,
Huining He ^{a, b, *}

a.
International Joint Laboratory of Ocular Diseases, School of Biomedical Engineering and Technology, Tianjin Medical University, Tianjin 300070, China
b.
Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China
c.
Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin 300070, China
d.
Department of Pharmacy, Affiliated Hospital of Shandong Second Medical University, Weifang 261031, China
e.
Tianjin Key Laboratory of Food and Biotechnology, School of Biotechnology and Food Science, Tianjin University of Commerce, Tianjin 300134, China

hehuining@tmu.edu.cn

Received Date: 16 May 2024
Revised Date: 11 July 2024
Accepted Date: 15 July 2024
Available Online: 15 July 2024

Figures(5)

Small interfering RNA (siRNA), a promising revolutionary therapy, faces delivery obstacles due to its poor targeting, strong charge negativity and macromolecular nature. Clinical-approved siRNAs can now only be delivered to the liver mediated by the chemically conjugated N-acetylgalactosamine (GalNAc) ligand, the conjugate can be effectively uptaken into cells through interaction with asialoglycoprotein receptor (ASGPR) highly expressed on liver hepatocytes. To further explore an efficient non-hepatic targeted delivery strategy, in this study, we designed a delivery system that chemically conjugated p53 siRNA to renal tubular cell-targeting peptides for targeting the kidney, which was suitable for industrial transformation. Results showed that peptide-siRNA conjugate could specifically enter renal tubular epithelial cells and silence target genes. In cisplatin-induced acute kidney injury (AKI) mice, peptide-siRNA conjugate blocked the p53-mediated apoptotic pathway and alleviated renal damage. The innovative proposed system to conjugate kidney-targeting peptides with siRNA achieved the efficient kidney-targeted delivery of siRNA and provided a prospective choice for treating AKI.
- siRNA delivery,
- Kidney target,
- Targeting peptide,
- Conjugate,
- Acute kidney injury
1. [1]
  W. Alshaer, H. Zureigat, A. Al. Karaki, et al., Eur. J. Pharmacol. 905 (2021) 174178. doi: 10.1016/j.ejphar.2021.174178
2. [2]
  Q. Wang, Q. Jiang, D. Li, et al., Chin. Chem. Lett. 35 (2024) 108683. doi: 10.1016/j.cclet.2023.108683
3. [3]
  M.L. Bobbin, J.J. Rossi, Annu. Rev. Pharmacol. Toxicol. 56 (2016) 103–122. doi: 10.1146/annurev-pharmtox-010715-103633
4. [4]
  H. Zogg, R. Singh, S. Ro, Int. J. Mol. Sci. 23 (5) (2022) 2736. doi: 10.3390/ijms23052736
5. [5]
  Y. Dong, D.J. Siegwart, D.G. Anderson, Adv. Drug Deliv. Rev. 144 (2019) 133–147. doi: 10.1016/j.addr.2019.05.004
6. [6]
  J. Wang, Z. Lu, M.G. Wientjes, J.L. Au, AAPS J. 12 (4) (2010) 492–503. doi: 10.1208/s12248-010-9210-4
7. [7]
  L. Zhang, Z. Dong, S. Yu, et al., Chin. Chem. Lett. 35 (2024) 109101. doi: 10.1016/j.cclet.2023.109101
8. [8]
  W. Cao, X. Zhang, R. Li, et al., J. Control. Release 368 (2024) 52–65. doi: 10.1117/12.3006552
9. [9]
  W. Tang, S. Panja, C.M. Jogdeo, et al., Biomaterials 285 (2022) 121562. doi: 10.1016/j.biomaterials.2022.121562
10. [10]
  J. Chen, H. Zhu, J. Xia, et al., Adv. Sci. 10 (2023) e2206306. doi: 10.1002/advs.202206306
11. [11]
  Q. Qin, M. Wang, Y. Zou, et al., MedComm Biomater. Appl. 2 (2023) e65. doi: 10.1002/mba2.65
12. [12]
  Y. Wang, C. Zhang, S. Han, et al., Chin. Chem. Lett. (2024), https://doi.org/10.1016/j.cclet.2024.109578. doi: 10.1016/j.cclet.2024.109578
13. [13]
  M. Moazzam, M. Zhang, A. Hussain, et al., Mol. Ther. 32 (2024) 284–312. doi: 10.1016/j.ymthe.2024.01.005
14. [14]
  J.W. Lee, J. Choi, Y. Choi, et al., J. Control. Release 351 (2022) 713–726. doi: 10.1016/j.jconrel.2022.09.040
15. [15]
  R. Liu, C. Luo, Z. Pang, et al., Chin. Chem. Lett. 34 (2023) 107518. doi: 10.1016/j.cclet.2022.05.032
16. [16]
  A. Maguregui, H. Abe, ChemBioChem 21 (2020) 1808–1815. doi: 10.1002/cbic.202000009
17. [17]
  A.D. Springer, S.F. Dowdy, Nucleic Acid Ther. 28 (2018) 109–118. doi: 10.1089/nat.2018.0736
18. [18]
  K.G. Rajeev, J.K. Nair, M. Jayaraman, et al., ChemBioChem 16 (2015) 903–908. doi: 10.1002/cbic.201500023
19. [19]
  B. Hu, S. Kong, Y. Weng, et al., Chin. Chem. Lett. 34 (2023) 108210. doi: 10.1016/j.cclet.2023.108210
20. [20]
  X. Liu, W. Wang, D. Samarsky, et al., Nucleic Acids Res. 42 (2014) 11805–11817. doi: 10.1093/nar/gku831
21. [21]
  S.R. Gonsalez, A.L. Cortês, R.C.D. Silva, et al., Pharmacol. Ther. 200 (2019) 1–12. doi: 10.1016/j.pharmthera.2019.04.001
22. [22]
  C. Ronco, R. Bellomo, J.A. Kellum, Lancet 394 (2019) 1949–1964. doi: 10.1016/S0140-6736(19)32563-2
23. [23]
  A. Vijayan, Nat. Rev. Nephrol. 17 (2021) 87–88. doi: 10.1038/s41581-020-00390-3
24. [24]
  E.A.J. Hoste, J.A. Kellum, N.M. Selby, et al., Nat. Rev. Nephrol. 14 (2018) 607–625. doi: 10.1038/s41581-018-0052-0
25. [25]
  J.A. Kellum, J.R. Prowle, Nat Rev Nephrol. 14 (2018) 217–230. doi: 10.1038/nrneph.2017.184
26. [26]
  R.L. Mehta, E.A. Burdmann, J. Cerdá, et al., Lancet 387 (2016) 2017–2025. doi: 10.1016/S0140-6736(16)30240-9
27. [27]
  Y. Nie, L. Wang, X. You, et al., J. Nanobiotechnol. 20 (2022) 505. doi: 10.1186/s12951-022-01712-2
28. [28]
  Y. Nie, L. Wang, S. Liu, et al., J. Nanobiotechnol. 22 (2024) 84. doi: 10.1186/s12951-024-02321-x
29. [29]
  C. Tang, Z. Ma, J. Zhu, et al., Pharmacol. Ther. 195 (2019) 5–12. doi: 10.1016/j.pharmthera.2018.10.013
30. [30]
  A. Wischnjow, D. Sarko, M. Janzer, et al., Bioconjug. Chem. 27 (2016) 1050–1057. doi: 10.1021/acs.bioconjchem.6b00057
31. [31]
  H.F. Horn, K.H. Vousden, Oncogene 26 (2007) 1306–1316. doi: 10.1038/sj.onc.1210263
32. [32]
  Y.L. Shen, L. Sun, Y.J. Hu, et al., Am. J. Transl. Res. 8 (2016) 4040–4053.
33. [33]
  M. Jiang, X. Yi, S. Hsu, et al., Am. J. Physiol. Renal Physiol. 287 (2004) F1140–F1147. doi: 10.1152/ajprenal.00262.2004
34. [34]
  J. Ye, E. Liu, J. Gong, et al., Theranostics 7 (2017) 2495–2508. doi: 10.7150/thno.19863
35. [35]
  S. Ghosh, Bioorg. Chem. 88 (2019) 102925. doi: 10.1016/j.bioorg.2019.102925
36. [36]
  S.M. Sears, L.J. Siskind, J. Am. Soc. Nephrol. 32 (2021) 1559–1567. doi: 10.1681/asn.2020101455
1. [1]
  Ruimiao Chang , Xinying Qu , Yuting Ye , Ying Qu , Bingyang Chu , Zhiyong Qian . Current advances in nanomedicine-based therapies for acute kidney injury. Chinese Chemical Letters, 2025, 36(10): 110802-. doi: 10.1016/j.cclet.2024.110802
2. [2]
  Liqing Chen , Zheming Zhang , Yanhong Liu , Chenfei Liu , Congcong Xiao , Liming Gong , Mingji Jin , Zhonggao Gao , Wei Huang . Systemically intravenous siRNA delivery into brain with a targeting and efficient polypeptide carrier and its evaluation on anti-glioma efficacy. Chinese Chemical Letters, 2025, 36(3): 110228-. doi: 10.1016/j.cclet.2024.110228
3. [3]
  Rui Li , Mengxi Zhu , Xiwen Hu , Jiaxuan Chen , Fei Yu , Stefan Barth , Lu Sun , Huining He . Overcoming endosomal/lysosomal barriers: Advanced strategies for cytosolic siRNA delivery. Chinese Chemical Letters, 2025, 36(9): 110736-. doi: 10.1016/j.cclet.2024.110736
4. [4]
  Jialin Guo , Mingrui Gu , Yahui Chen , Tao Xiong , Yiyang Zhang , Simin Chen , Mingle Li , Xiaoqiang Chen , Xiaojun Peng . Nucleic acid delivery by lipid nanoparticles for organ targeting. Chinese Chemical Letters, 2025, 36(11): 110849-. doi: 10.1016/j.cclet.2025.110849
5. [5]
  Weiyu Chen , Zenghui Li , Chenguang Zhao , Lisha Zha , Junfeng Shi , Dan Yuan . Enzyme-modulate conformational changes in amphiphile peptide for selectively cell delivery. Chinese Chemical Letters, 2024, 35(12): 109628-. doi: 10.1016/j.cclet.2024.109628
6. [6]
  Yao-Hua Gu , Yu Chen , Qing Li , Neng-Bin Xie , Xue Xing , Jun Xiong , Min Hu , Tian-Zhou Li , Ke-Yu Yuan , Yu Liu , Tang Tang , Fan He , Bi-Feng Yuan . Metabolome profiling by widely-targeted metabolomics and biomarker panel selection using machine-learning for patients in different stages of chronic kidney disease. Chinese Chemical Letters, 2024, 35(11): 109627-. doi: 10.1016/j.cclet.2024.109627
7. [7]
  Kai Wang , Yun Wang , Lihang Wang , Zhuhai Li , Xi Yu , Xuanhe You , Diwei Wu , Yueming Song , Jiancheng Zeng , Zongke Zhou , Shishu Huang , Yunfeng Lin . Therapeutic siRNA targeting CC chemokine receptor 2 loaded with tetrahedral framework nucleic acid alleviates neuropathic pain by regulating microglial polarization. Chinese Chemical Letters, 2025, 36(3): 109868-. doi: 10.1016/j.cclet.2024.109868
8. [8]
  Luyu Zhang , Zirong Dong , Shuai Yu , Guangyue Li , Weiwen Kong , Wenjuan Liu , Haisheng He , Yi Lu , Wei Wu , Jianping Qi . Ionic liquid-based in situ dynamically self-assembled cationic lipid nanocomplexes (CLNs) for enhanced intranasal siRNA delivery. Chinese Chemical Letters, 2024, 35(7): 109101-. doi: 10.1016/j.cclet.2023.109101
9. [9]
  Yunjie Dang , Yanru Feng , Xiao Chen , Chaoxing He , Shujie Wei , Dingyang Liu , Jinlong Qi , Huaxing Zhang , Shaokun Yang , Zhiyun Niu , Bai Xiang . Development of a multi-level pH-responsive lipid nanoplatform for efficient co-delivery of siRNA and small-molecule drugs in tumor treatment. Chinese Chemical Letters, 2024, 35(12): 109660-. doi: 10.1016/j.cclet.2024.109660
10. [10]
  Weijian Zhang , Xianyu Deng , Liying Wang , Jian Wang , Xiuting Guo , Lianggui Huang , Xinyi Wang , Jun Wu , Linjia Jiang . Poly(ferulic acid) nanocarrier enhances chemotherapy sensitivity of acute myeloid leukemia by selectively targeting inflammatory macrophages. Chinese Chemical Letters, 2024, 35(9): 109422-. doi: 10.1016/j.cclet.2023.109422
11. [11]
  Qiang Li , Jiangbo Fan , Hongkai Mu , Lin Chen , Yongzhen Yang , Shiping Yu . Nucleus-targeting orange-emissive carbon dots delivery adriamycin for enhanced anti-liver cancer therapy. Chinese Chemical Letters, 2024, 35(6): 108947-. doi: 10.1016/j.cclet.2023.108947
12. [12]
  Xiaoshuai Wu , Bailei Wang , Yichen Li , Xiaoxuan Guan , Mingjing Yin , Wenquan Lv , Yin Chen , Fei Lu , Tao Qin , Huyang Gao , Weiqian Jin , Yifu Huang , Cuiping Li , Ming Gao , Junyu Lu . NIR driven catalytic enhanced acute lung injury therapy by using polydopamine@Co nanozyme via scavenging ROS. Chinese Chemical Letters, 2025, 36(2): 110211-. doi: 10.1016/j.cclet.2024.110211
13. [13]
  Dandan Tang , Ningge Xu , Yuyang Fu , Wei Peng , Jinsheng Wu , Heng Liu , Fabiao Yu . Rationally designed an innovative proximity labeling near-infrared fluorogenic probe for imaging of peroxynitrite in acute lung injury. Chinese Chemical Letters, 2025, 36(5): 110082-. doi: 10.1016/j.cclet.2024.110082
14. [14]
  Liangyu Zhang , Lei Lei , Zhuangzhuang Zhao , Guizhi Yang , Kaitao Wang , Liying Wang , Ningxin Zhang , Yanjia Ai , Xinqing Ma , Guannan Liu , Meng Zhao , Jun Wu , Dongjun Lin , Chun Chen . Enhanced venetoclax delivery using l-phenylalanine nanocarriers in acute myeloid leukemia treatment. Chinese Chemical Letters, 2025, 36(6): 110316-. doi: 10.1016/j.cclet.2024.110316
15. [15]
  Mengxing Liu , Jing Liu , Hongxing Zhang , Jianan Tao , Peiwen Fan , Xin Lv , Wei Guo . One-pot accessing of meso–aryl heptamethine indocyanine NIR fluorophores and potential application in developing dye-antibody conjugate for imaging tumor. Chinese Chemical Letters, 2025, 36(4): 109994-. doi: 10.1016/j.cclet.2024.109994
16. [16]
  Jiaqi Huang , Renjiang Kong , Yanmei Li , Ni Yan , Yeyang Wu , Ziwen Qiu , Zhenming Lu , Xiaona Rao , Shiying Li , Hong Cheng . Feedback enhanced tumor targeting delivery of albumin-based nanomedicine to amplify photodynamic therapy by regulating AMPK signaling and inhibiting GSTs. Chinese Chemical Letters, 2024, 35(8): 109254-. doi: 10.1016/j.cclet.2023.109254
17. [17]
  Boyuan Liu , Zixu Liu , Ping Wang , Yu Zhang , Haibing He , Tian Yin , Jingxin Gou , Xing Tang . Nanomedicine-based targeting delivery systems for peritoneal cavity localized therapy: A promising treatment of ovarian cancer and its peritoneal metastasis. Chinese Chemical Letters, 2025, 36(6): 110229-. doi: 10.1016/j.cclet.2024.110229
18. [18]
  Qi Huang , Jun Liao , Jingjing Li , Zhengyan Gu , Xinkang Zhang , Mingxue Sun , Wenqi Meng , Guanchao Mao , Zhipeng Pei , Shanshan Zhang , Songling Li , Chuan Zhang , Yunqin Wang , Jihao Liu , Tingbin Shu , Min Tao , Ying Lu , Kai Xiao , Qingqiang Xu , Jincai Lu . Curcumin-loaded ceria nanoenzymes for dual-action suppression of inflammation and alleviation of oxidative damage in the treatment of acute lung injury. Chinese Chemical Letters, 2025, 36(4): 109914-. doi: 10.1016/j.cclet.2024.109914
19. [19]
  Mingrui Zhang , Lingyu Jin , Yuda Zhu , Junfeng Kou , Bo Liu , Jing Chen , Xiaolin Zhong , Xianghua Wu , Junfeng Zhang , Wenxiu Ren . A near-infrared Ⅱ fluorescent dye based on oxanthracene: Real-time imaging of drug-induced acute liver injury and photothermal therapy for tumor. Chinese Chemical Letters, 2025, 36(10): 110772-. doi: 10.1016/j.cclet.2024.110772
20. [20]
  Ru Ding , Chunfei Wang , E Lv , Jingjing Zhao , Xucong Zhou , Yuanyi Li , Ying Wang , Bingxue Li , Lixia Zhang , Jin Zhou . A near-infrared fluorescent probe based on Au³⁺/Pd²⁺ complexes for glutathione sensing: Applications in acute liver injury, hepatocellular carcinoma, and ferroptosis exploration. Chinese Chemical Letters, 2025, 36(11): 111497-. doi: 10.1016/j.cclet.2025.111497

Get Citation

PDF

XML

Metrics

PDF Downloads(0)
Abstract views(1070)
HTML views(57)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142